Sign up Canada
Proactive Investors - Run By Investors For Investors

VolitionRx to take part in Bank of America Merrill Lynch's 2018 Health Care Conference

The conference takes place at the Encore Hotel in Las Vegas from May 15-17
Cancer cells
The cancer-test specialist is taking part in largest ever colorectal cancer screening study

Cancer test specialist VolitionRx Ltd (NYSEMKTS:VNRX) will participate in Bank of America Merrill Lynch’s 2018 Health Care Conference, which is being held Tuesday through Thursday of this week.

At the conference, which takes place at the Encore Hotel in Las Vegas, Scott Powell, chief financial officer of Volition America, will provide an update about the company’s key business, clinical, regulatory and operational achievements.

Earlier this year, VolitionRx hailed positive interim results from its huge trial in Denmark concerning colorectal cancer (CRC), which point to being able to detect early signs of the disease.

The ongoing study is in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark and involves 680 subjects from the Danish National CRC Screening Program.

READ: VolitionRx hails interim results of Danish trial for screening colorectal cancer

Meanwhile, in the US, VolitionRx is taking part in what is believed to be the largest ever colorectal cancer screening study in collaboration with the National Cancer Institute's Early Detection Research Network with a cohort of over 13,500 subjects.

Collection is underway and is expected to be completed in 2020.

In early trade, shares of VolitionRx were 2.9% higher at US$2.15.

View full VNRX profile View Profile

VolitionRx Timeline

Related Articles

blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p
Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
affimer technology
May 01 2018
The company is making progress with its lead immuno-oncology programmes
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use